Successful rapid desensitization for cetuximab-induced anaphylaxis.
10.4168/aard.2015.3.4.294
- Author:
Ha Kyeong WON
1
;
Sung Do MOON
;
Ji Su SHIM
;
Soo Jie CHUNG
;
Gun Woo KIM
;
Su Jeong KIM
;
Han Ki PARK
;
Hye Ryun KANG
Author Information
1. Department of Internal Medicine, Seoul National University Medical Research Center, Seoul National University College of Medicine, Seoul, Korea. helenmed@snu.ac.kr
- Publication Type:Case Report
- Keywords:
Cetuximab;
Hypersensitivity;
Immunologic desensitization
- MeSH:
Aged;
Anaphylaxis*;
Desensitization, Immunologic;
Humans;
Hypersensitivity;
Immunoglobulins;
Male;
Sigmoid Neoplasms;
United States Food and Drug Administration;
Cetuximab
- From:Allergy, Asthma & Respiratory Disease
2015;3(4):294-296
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Cetuximab, a chimeric mouse-human immunoglobulin, is an antiepidermal growth factor receptor monoclonal antibody. It has been approved by the U.S. Food and Drug Administration for the treatment of metastatic colorectal and head/neck cancer, but can cause fatal hypersensitivity reactions in some patients. A 66-year-old male with metastatic sigmoid cancer had cetuximab-induced anaphylaxis when the first dose of cetuximab was administered. Cetuximab was safely readministered for another 15 cycles based on the rapid desensitization protocol. We experienced a case of cetuximab-induced anaphylaxis on the first exposure which was successfully managed by rapid desensitization.
